Posted Date: May 15, 2019
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
This is a study using immunotherapy (nivolumab) in patients with recurrent head and neck cancer after failing at least radiation therapy requiring a salvage surgical resection. Patients receive 6 months of monthly nivolumab after surgery in attempt to prevent subsequent recurrence of cancer.
To Be Eligible To Participate In This Study, Patients Must Have Undergone Surgery For Head And Neck Cancer After Failing Radiation Treatment. Patients Must Not Have An Autoimmune Disease Or Require Steroids.
Head And Neck Cancer, Resection, Phase Ii, Ucci-Hn-17-01
For More Information:
Uc Cancer Institute